TY - JOUR T1 - Global prediction for monkeypox epidemic JF - medRxiv DO - 10.1101/2022.10.21.22280978 SP - 2022.10.21.22280978 AU - Li Zhang AU - Jianping Huang AU - Bin Chen AU - Yingjie Zhao AU - Danfen Wang AU - Wei Yan Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/10/22/2022.10.21.22280978.abstract N2 - The monkeypox epidemic has now spread all over the world and has become an epidemic of widespread concern in the international community. Before the emergence of targeted vaccines and specific drugs, it is necessary to numerically simulate and predict the epidemic. In order to better understand and grasp its transmission situation, and put forward some countermeasures accordingly, we predicted and simulated monkeypox transmission and vaccination scenarios using models developed for COVID-19 predictions. The results suggest the monkeypox epidemic will spread to almost all countries in the world by the end of 2022 based on modified SEIR model prediction. The total number of people infected with monkeypox will reach 100,000. The top five countries will be the United States, Brazil, Germany, France and Britain with more than 28000, 20000, 4000, 4500 and 4000 cases respectively. If 30% of the population is vaccinated, the number of infected people will drop by 35%.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNational science Foundation of China (41521004) Special Fund Project of Guiding Scientific and Technological Innovation Development of Gansu Province (2019ZX-06)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors All data produced in the present work are contained in the manuscript https://www.monkeypox.global.health ER -